LONDON, Nov. 29, 2016 /PRNewswire/ -- Mechanical heart valve is an artificial heart valve implanted in patients suffering from indicated diseases such as aortic stenosis or mitral regurgitation. Tissue heart valves are the biological valves harvested from cow heart sac (bovine) or porcine (pig) heart valves mounted on a stent or used without a stent to replace a dysfunctional heart valve. The global prosthetic heart valve market revenue is projected to register a CAGR of 12.0% during the forecast period (2016-2026) and reach a market valuation of US$ 19.60 Bn by the end of 2026.
Rising prevalence of valvular heart disease (VHD) expected to augment market growth
Increasing occurrences of valvular heart disease (VHD) is one of the primary drivers impacting the global prosthetic heart valve market. Other factors fuelling the demand for prosthetic heart valves include regulatory approval for heart valves, integration of technological advancements, and increasing number of heart valve implantation procedures. Prosthetic heart values are an effective alternative to cumbersome open heart surgery, and this is one of the main reasons for a global preference for prosthetic heart valves.
However, high costs associated with transcatheter heart valve products, procedure related risks and complications, and product recalls are some restraints likely to hamper the growth of the global prosthetic heart valve market over the forecast period.
By Product Type
By End User
Mechanical Heart Valves
Mechanical Aortic Valve
Mechanical Mitral Valve
Biological/Tissue Heart Valves
Tissue Aortic Valve
Tissue Mitral Valve
Transcatheter Heart Valves
Transcatheter Aortic Valve
Transcatheter Mitral Valve
Ambulatory Surgery Centres
Latin America Excluding Brazil
Asia Pacific Excluding Japan (APEJ)
Middle East & Africa (MEA)
Tissue Heart Valves product type segment expected to dominate the global prosthetic heart valve market in terms of value
The Tissue Heart Valves segment is anticipated to register a CAGR of 12.2% during the forecast period. The Transcatheter Heart Valves segment accounted for 27.2% value share of the global prosthetic heart valve market in 2015 and is estimated to account for over 31.0% revenue share of the global prosthetic heart valve market by the end of 2026.
Hospitals end user segment likely to project increased revenue growth during the forecast period
The Hospitals segment is anticipated to be valued at US$ 4,717.2 Mn by the end of 2016 and register a CAGR of 12.2% over the forecast period to reach a market valuation of US$ 14.9 Bn by the end of 2026. The Hospitals segment is projected to remain dominant in the global prosthetic heart valve market in terms of value over the forecast period, attributed to a large number of cardiac patients opting for hospitals to undergo treatment.
North America, Western Europe, and APEJ expected to be the fastest growing regional markets throughout the forecast period
North America and Western Europe accounted for over half the revenue share of the global prosthetic heart valve market in 2015. The North America prosthetic heart valve market accounted for a market share of 41.0% in 2015 and is expected to retain its dominance in terms of revenue in the global prosthetic heart valve market throughout the forecast period. Increased THV procedures coupled with rising adoption of technological advancements in an effort to reduce treatment duration for high conventional surgical risk patients is expected to result in significant growth of the global prosthetic heart valve market in North America. The Western Europe prosthetic heart valve market is expected to account for the second largest market value share owing to product maturity and increased awareness levels among the population in the region.
prosthetic heart valve market
Leading market players are concentrating on providing differentiated treatment options to patients to retain market share
Edwards Lifesciences Corporation, St. Jude Medical, Inc., Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, SYMETIS, LivaNova PLC, CryoLife, Inc., Braile Biomedica, Colibri Heart Valve LLC, and JenaValve Technology, Inc. are some of the leading players operating in the global prosthetic heart valve market. Top companies are focussing on delivering differentiated therapies to cardiac patients and are strengthening their foothold in the global prosthetic heart valve market through strategic collaborations and acquisitions.
Download the full report: https://www.reportbuyer.com/product/4394421/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48